Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
European Journal of Cancer · 2026-07 · 243 · 116816
DOI: 10.1016/j.ejca.2026.116816 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-07. Verfasst von Marit Ahrens und 35 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic II, Goethe University, Frankfurt, Germany. Hauptthemen laut MEDLINE: Ipilimumab, Carcinoma, Renal Cell, Kidney Neoplasms, Nivolumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb Foundation Inc, Goethe-Universität Frankfurt am Main, Bristol-Myers Squibb.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Clinic II, Goethe University, Frankfurt, Germany.
- Netherlands Cancer Institute, Amsterdam and Leiden University Medical Center, Leiden, Netherlands; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
- Institut Gustave Roussy, Paris, France.
- Department of Medical Oncology, University Hospital Bordeaux, Bordeaux, France.
- Royal Free London NHS Foundation Trust, London, UK.
- Department of Medical Oncology, Institut Paoli-Calmettes, Aix Marseille Univ, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France.
Förderung
- Bristol-Myers Squibb Foundation Inc
- Goethe-Universität Frankfurt am Main
- Bristol-Myers Squibb
Zitieren
APA
Ahrens, M., Haanen, J., Albiges, L., Goupil, M. G., Boleti, E., Gravis, G., Fléchon, A., Grimm, M. O., Bedke, J., Barthélémy, P., Castellano, D., Mellado, B., Ivanyi, P., Rottey, S., Flörcken, A., Suárez, C., Maroto, J. P., Grünwald, V., Oosting, S., …, & Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN) (2026). Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. European Journal of Cancer, 243, 116816. https://doi.org/10.1016/j.ejca.2026.116816
Vancouver
Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, et al. Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. European Journal of Cancer. 2026;243:116816. doi:10.1016/j.ejca.2026.116816
BibTeX
@article{Ahrens2026,
author = {Ahrens, Marit and Haanen, John and Albiges, Laurence and Goupil, Marine Gross and Boleti, Ekaterini and Gravis, Gwenaelle and Fléchon, Aude and Grimm, Marc Oliver and Bedke, Jens and Barthélémy, Philippe and Castellano, Daniel and Mellado, Begona and Ivanyi, Philipp and Rottey, Sylvie and Flörcken, Anne and Suárez, Cristina and Maroto, Jose P and Grünwald, Viktor and Oosting, Sjoukje and Kopecky, Jindrich and Zschäbitz, Stefanie and Boegemann, Martin and Buchler, Tomas and Niegisch, Guenter and Goebell, Peter J and Waddell, Tom and Joly, Florence and Priou, Frank and Retz, Margitta and Siemer, Stefan and Zimmermann, Uwe and Deckbar, Dorothee and Burkholder, Iris and Hartmann, Arndt and Bergmann, Lothar and Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN), Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN)},
title = {Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review},
journal = {European Journal of Cancer},
year = {2026},
volume = {243},
pages = {116816},
doi = {10.1016/j.ejca.2026.116816}
}
EUVIMED